
FDA approves Dechra’s generic antibiotic
pharmafile | September 9, 2016 | News story | Medical Communications, Sales and Marketing | Dechra, Putney, antiobiotic, generic
Dechra has announced that the US Food and Drug Administration (FDA) has approved its generic antibiotic. The product will be first generic drug to enter the sizeable antibiotic market, according to the company.
The approval is doubly significant for the company as it is the first they have achieved through recently-acquired US-based business Putney.
Dechra’s CEO Ian Page commented: “We are delighted to receive this approval which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra’s position in the US market.”
Matt Fellows
Related Content

FDA greenlights Glenmark’s generic version of Biogen’s Tecfidera in relapsing multiple sclerosis
Glenmark Pharma will be celebrating after it secured FDA approval in the US to market …

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute
The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …

Mylan launches generic version of Gilead’s remdesivir for COVID-19 patients in India
Mylan has launched its own generic version of Gilead’s remdesivir on the Indian market for …






